NCT06036771Completed
Voice-activated Intelligent Personal Assistant (VIPA) Intervention for People With Parkinson's Disease
Efficacy of the Voice-activated Intelligent Personal Assistant (VIPA) Intervention on Psychosocial Well-being Among People With Parkinson's Disease: A Pilot Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
This pilot randomized control trial (RCT) aims to develop a Voice-activated Intelligent Personal Assistance (VIPA) user protocol and study its feasibility and preliminary efficacy among 48 People with Parkinson's disease (PWP). The research questions are: Phase 1: 1. What components should be included in the VIPA user protocol community-dwelling PWP? 2. Is it feasible to implement the VIPA intervention in the PD population? 3 focus group interviews and 3 cognitive interviews will be held to formulate the VIPA user protocol. 5 healthcare and information technology experts will be invited to rate the relevancy of the formulated protocol and the item content validity index will be calculated by the researcher. Phase 2: 1. What is the preliminary efficacy of VIPA intervention on SOC and psychosocial well-being? 2. Can such effect sustain for 4 weeks? 3. What is the users' experience on the VIPA intervention? 48 participants will be randomized into the intervention group (IG) and control group (CG). During the 8-week intervention period, IG participants will receive the following materials: 1. User protocol 2. Designate VIPA 3. 30-minute VIPA training on day 1 4. technical support hotline. CG participants will receive usual care, no intervention will be provided to CG participants, and they will continue their daily life during the intervention period. The researcher will compare both groups to study the feasibility and preliminary efficacy of the VIPA on the participants' psychosocial well-being and sense of coherence.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 21 Aug 2023
- Start date
- 6 Aug 2023
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- The Hong Kong Polytechnic University
- Diseases
- Parkinson disease
- NCT number
- NCT06036771
What you commit to
- Study type: Interventional
- Participants enrolled: 48
- From 6 Aug 2023 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe voice impairment
- Dementia patients (MoCA score \<21)
Other
- PWP or their caregivers that fails to provide valid consent
- Individuals with hearing loss in both ears
- PWP will leave Hong Kong during the intervention period.
Who the study is looking for
- Cantonese-speaking Hong Kong permanent resident
- Diagnosed with Parkinson's disease
- Level 1-4 in the H\&Y scale (Hoehn \& Yahr, 1967)
- Not currently using or owning VIPA
- Has stable Wi-Fi connection at home.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Hong Kong Polytechnic University Coordinator of this site? Confirm its status | Kowloon | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.